{"generic":"Imiglucerase","drugs":["Cerezyme","Imiglucerase"],"mono":{"0":{"id":"jrnns0","title":"Generic Names","mono":"Imiglucerase"},"1":{"id":"jrnns1","title":"Dosing and Indications","sub":{"0":{"id":"jrnns1b4","title":"Adult Dosing","mono":"<b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> usual dosage, 60 units\/kg IV over 1to 2 hr every 2 weeks; may range from 2.5 units\/kg 3 times weekly to 60 units\/kg once every 2 weeks; disease severity may dictate that treatment initiate at a relatively high or frequent dose "},"1":{"id":"jrnns1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness have not been established in children younger than 2 years of age<\/li><li><b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> (2 yr and older) usual dosage, 60 units\/kg IV over 1to 2 hr every 2 weeks; may range from 2.5 units\/kg 3 times weekly to 60 units\/kg once every 2 weeks; disease severity may dictate that treatment initiate at a relatively high or frequent dose<\/li><\/ul>"},"3":{"id":"jrnns1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Non-neuropathic Gaucher's disease, chronic, symptomatic<br\/>"}}},"3":{"id":"jrnns3","title":"Contraindications\/Warnings","sub":[{"id":"jrnns3b9","title":"Contraindications","mono":"none reported; carefully reevaluate treatment if there is clinical evidence of hypersensitivity to the product<br\/>"},{"id":"jrnns3b10","title":"Precautions","mono":"<ul><li>presence of IgG antibodies or hypersensitivity to imiglucerase<\/li><li>approximately 15% of patients developed IgG antibody during the first year of therapy and approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity<\/li><\/ul>"},{"id":"jrnns3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jrnns3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jrnns5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension, Tachyarrhythmia<\/li><li><b>Dermatologic:<\/b>Cyanosis, Flushing, Pruritus, Rash, Urticaria<\/li><li><b>Endocrine metabolic:<\/b>Shivering<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Diarrhea, Nausea<\/li><li><b>Musculoskeletal:<\/b>Backache<\/li><li><b>Neurologic:<\/b>Dizziness, Headache<\/li><li><b>Respiratory:<\/b>Chest discomfort, Disorder of respiratory system<\/li><li><b>Other:<\/b>Angioedema, Fatigue, Fever<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylactoid reaction (rare)<br\/>"},"6":{"id":"jrnns6","title":"Drug Name Info","sub":{"0":{"id":"jrnns6b17","title":"US Trade Names","mono":"Cerezyme<br\/>"},"2":{"id":"jrnns6b19","title":"Class","mono":"<ul><li>Digestant<\/li><li>Enzyme<\/li><li>Gastrointestinal Agent<\/li><\/ul>"},"3":{"id":"jrnns6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jrnns6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jrnns7","title":"Mechanism Of Action","mono":"Systemic: Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.  <br\/>"},"8":{"id":"jrnns8","title":"Pharmacokinetics","sub":{"1":{"id":"jrnns8b24","title":"Distribution","mono":"Systemic: Vd: 0.09 to 0.15 L\/kg <br\/>"},"4":{"id":"jrnns8b27","title":"Elimination Half Life","mono":"Systemic: 3.6 to 10.4 min <br\/>"}}},"9":{"id":"jrnns9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>dilute with NS to a final volume of 100 to 200 mL and infuse over 1 to 2 hr<\/li><li>use an in-line low protein binding 0.2 micron filter during administration<\/li><\/ul>"},"10":{"id":"jrnns10","title":"Monitoring","mono":"<ul><li>improvement in hematologic parameters including hemoglobin, hematocrit, and erythrocyte and platelet counts<\/li><li>CBC<\/li><li>IgG antibody formation, periodic during first year of treatment<\/li><li>respiratory symptoms without fever; evaluate for pulmonary hypertension<\/li><\/ul>"},"11":{"id":"jrnns11","title":"How Supplied","mono":"<b>Cerezyme<\/b><br\/>Intravenous Powder for Solution: 400 U<br\/>"},"13":{"id":"jrnns13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause flushing, shivering, abdominal pain, diarrhea, nausea, back pain, dizziness, headache, chest discomfort, angioedema (deep swelling around eyes and lips and sometimes hands and feet), fatigue, or fever.<\/li><li>Instruct patient to report signs\/symptoms of cyanosis, hypotension, or tachyarrhythmia.<\/li><\/ul>"}}}